성인 예방접종 안내서 제2판 2018 [사람유두종바이러스 감염증]

※ 만 27세 이후 여성에서 암 예방 효과는 입증되지 않았으나 만 27세 이상이라도 성생활을 시작하지 않았거나 HPV 노출 기회가 적은 여성의 경우는 이론적으로 암 예방 효과를 기대할 수 있음.

​

※ 젊은 성인 및 청소년에서 예방접종 후 실신 보고 빈도가 높음. 실신으로 인한 외상 예방을 위해 앉거나

누워서 접종하고, 접종 후에도 그 상태로 20-30분간 관찰. 가다실 예방접종 후 실신 가능성이 잇으며 이로 인한 신체 상해 가능성이 있으므로 백신 접종 후 앉아서 경과 관찰이 필요.

​

Data from both registration trials and post-licensure safety surveillance systems demonstrate that the vaccine is safe and well tolerated apart from mild injection site reactions. Postvaccination syncopal events have emerged as a potential serious adverse effect, although it does not appear unique to HPV vaccination, since syncope after vaccination occurs with other vaccines administered to adolescents. A waiting time after vaccination is recommended to try to reduce the likelihood of injury from possible syncope.

​

Among serious events, headache, nausea, vomiting, fatigue, dizziness, syncope, and generalized weakness were the most frequently reported.

​

There does appear to be an increased risk of syncope with the quadrivalent vaccine, but whether this is unique to this vaccine is unclear.

​

The incidence of syncope among adolescents has increased overall with the introduction of other routine immunizations as well, such as meningococcal vaccine.

​

REF. UpToDate 2019.10.26